Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Thermo Scientific Enters into a Long-Term Agreement with Fujirebio

Published: Thursday, November 22, 2012
Last Updated: Wednesday, November 21, 2012
Bookmark and Share
Combination of Thermo Scientific B•R•A•H•M•S PCT assay and Lumipulse platforms to test patients suspected of having sepsis.

Thermo Fisher Scientific Inc. has announced that it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse™ family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

The agreement focuses on Japan, where Fujirebio’s Lumipulse product line is placed in a significant number of hospitals and clinical reference labs and will be extended with future placements of Lumipulse platforms in other markets worldwide.

The PCT assay is available worldwide on several different laboratory instruments from strategic license partners.

In Europe, the PCT test, which has been the gold standard for the early detection of sepsis in critically ill patients, helps doctors to make an early determination whether an infection is bacterial or viral and quickly provides information on the severity of a patient’s condition for appropriate treatment and therapy monitoring.

In Japan, the PCT assay is used in patients suspected of having sepsis. Broader availability of PCT testing for diagnosing sepsis will lead to improved hospital management.

“This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patient’s outcome,” said Marc Tremblay, president of Thermo Fisher Scientific’s Clinical Diagnostics business.

Tremblay continued, “Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost-savings.”

Sepsis causes more deaths per year than prostate cancer, breast cancer and HIV/AIDS combined and claims 10,000 lives worldwide every day.

Prevalence has increased dramatically over the last decade, increasing in the developed world by 8 to 13 percent annually, making it one of the most pressing healthcare challenges faced by the world.

Severe sepsis strikes more than 750,000 Americans each year, and between 28 and 50 percent patients affected die within the first month of diagnosis.

Hospital costs to treat severe sepsis in the U.S. are estimated at $16 billion dollars annually.

Much of this cost is attributed to misdiagnosis or delayed diagnosis, making rapid, more reliable detection a national, if not global, imperative.

Research published in the journal Critical Care Medicine showed that each hour of delay in therapy can decrease chances of patient survival by 7.6 percent.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ATCC, CDC and Thermo Partner on Public Health RT-PCR Assay
New technology supports HIV-1 drug resistance surveillance in resource-limited countries.
Wednesday, June 25, 2014
Biodesign Institute, Thermo Fisher Partner on $9M Radiation Test
Partnership enters a new, $9M phase of a project to produce a diagnostic test to rapidly measure an individual’s level of absorption of ionizing radiation.
Wednesday, June 04, 2014
Thermo, Nuclea Biotechnologies Collaborate to Develop Diabetes Markers
Companies pooling their expertise to develop novel multiplexed research methods for high-throughput quantification of native insulin and its therapeutic analogs.
Monday, June 02, 2014
Thermo Completes Life Tech Acquisition
The completion of the transaction follows the receipt of all required regulatory approvals.
Tuesday, February 04, 2014
Thermo Receives EC Clearance for Life Tech Acquisition
Thermo Fisher Scientific announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation.
Tuesday, November 26, 2013
Thermo Fisher Scientific Announces Collaboration to Establish New Tokyo Biomarker Research Center
Thermo Fisher Scientific Inc., today announced a landmark collaboration that aims to introduce mass spectrometry-based workflows and technologies into Japan to advance personalized medicine and healthcare.
Monday, July 26, 2010
Thermo Fisher Scientific’s Mass Spectrometry Technology Helps Children’s Hospital Boston Isolate Biomarker for Acute Pediatric Appendicitis
Children’s Hospital research team believes discovery will lead to more accurate, efficient diagnosis
Tuesday, December 15, 2009
Thermo Fisher Scientific Collaborates with the Institute of Cancer Research to Create Proteomics Laboratory
The ICR's new, proteomics laboratory is equipped with a complete Thermo Scientific proteomics workflow.
Friday, July 24, 2009
Thermo Fisher Scientific Wins Innovation Award in Informatics for Second Consecutive Year
Thermo Scientific Nautilus LIMS for Biobanks increases throughput at Hunt Research Centre and Biobank.
Thursday, July 16, 2009
Cancer Research Technology Selects Maybridge Fragments for Lead Discovery Programmes
CRT purchases 2,000 Maybridge Fragments as the foundation of its new fragment screening library.
Friday, May 22, 2009
Thermo Fisher Scientific Welcomes New Members to RNAi Global Initiative
The new member institutions include the Children's Hospital of Eastern Ontario Research Institute and the University of Leiden in Amsterdam.
Monday, March 02, 2009
Thermo Fisher Scientific Joins Microsoft in the Bio IT Alliance
The BioIT Alliance is an organization of more than 40 pharmaceutical, biotech, hardware and software companies working together to realize the potential of personalized medicine.
Friday, February 02, 2007
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos